GLP-1 research peptides compared: semaglutide, tirzepatide and retatrutide
Three compounds, one shorthand — "GLP-1 peptides" — and three different analytical problems. Treating them as interchangeable reference materials is the most common specification error we see in this category.
The comparison, at a glance
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Reported receptor profile | GLP-1 receptor agonist | GIP / GLP-1 dual agonist | GLP-1 / GIP / glucagon triple agonist |
| Reference molecular weight | ≈4113.6 g/mol | ≈4813.5 g/mol | ≈4731.4 g/mol |
| Backbone class | Modified GLP-1 analogue | Modified dual-agonist peptide | Modified triple-agonist peptide |
| Half-life strategy (reported) | Albumin binding via fatty-acid side chain | Albumin binding via fatty-acid side chain | Albumin binding via fatty-acid side chain |
| Analytical burden | High — modified side chain, hydrophobic character | High — long sequence, hydrophobic modifications | High — long sequence, triple-pharmacology design |
| Typical research formats | 2–50 mg lyophilized powder | 2–60 mg lyophilized powder | 5–60 mg lyophilized powder |
Molecular weights are reference values for the parent compounds; salt form and counter-ion affect the mass of the actual material. Receptor assignments are as reported in the public literature and are not a claim about effects.
Why the class label is misleading
"GLP-1 peptide" is a pharmacological shorthand, not a specification. The three molecules differ in sequence length, side-chain chemistry, hydrophobicity and receptor profile. Those differences change three practical things:
- Analytical behaviour: longer, more hydrophobic sequences produce more complex impurity profiles and can tail on standard RP-HPLC methods.
- Solubility and handling: hydrophobic modifications affect dissolution and adsorption behaviour; a solvent that works for one may not work for another.
- Documentation expectations: a COA that is adequate for a short peptide is thin for a 39–44 residue modified analogue.
Our position: each of these compounds is its own specification problem. Buyers who write one generic "GLP-1 peptide" specification and apply it to all three are not simplifying procurement — they are hiding the variables that matter.
Semaglutide: the reference analogue
Semaglutide is a modified GLP-1 analogue with a fatty-acid side chain that supports albumin binding. The modification is what makes the molecule analytically interesting: the side chain increases hydrophobicity, shifts retention on RP-HPLC, and creates a distinct impurity pattern compared with unmodified GLP-1 sequences.
Practical consequences for buyers:
- HPLC methods must resolve the modified parent from side-chain-related impurities.
- MS confirmation should be checked against the expected mass of the modified sequence, not the unmodified backbone.
- Solubility in purely aqueous solvent can be limited; the COA's recommended solvent should be followed.
Semaglutide analytical profile covers sequence, modifications and method notes.
Tirzepatide: the dual agonist
Tirzepatide is a longer modified peptide reported as a GIP/GLP-1 dual agonist. The longer sequence and hydrophobic modifications raise the analytical bar: more coupling steps, a more complex impurity profile, and a greater chance that a generic HPLC gradient will under-resolve the main peak.
What to verify:
- Mass confirmation for the full modified sequence
- Chromatographic resolution of the parent from deletion sequences
- Water content and net peptide content — the economic difference at this molecular weight is not trivial
Tirzepatide analytical profile has the detail.
Retatrutide: the triple agonist
Retatrutide is reported as a GLP-1/GIP/glucagon triple agonist. It is the newest of the three in research supply, which has two consequences: fewer independent analytical references are publicly available, and the market contains more material of uncertain provenance. That makes documentation discipline more important, not less.
Buyers should be especially careful about:
- Suppliers who cannot provide a batch-linked chromatogram for this specific compound
- COAs copied from a related compound with the name changed
- Molecular-weight claims that do not match the published sequence
Retatrutide analytical profile covers the verification points.
Sourcing verification for this category
The minimum evidence set
These are among the most counterfeited research peptides, for the same reason they are in demand: high value per gram and a buyer base that often cannot run full identity testing. The verification standard should be higher than for commodity peptides.
| Check | Minimum evidence | Why it matters here |
|---|---|---|
| Identity | MS spectrum matching the modified sequence | Close analogues and truncations can pass a casual glance |
| Purity | HPLC chromatogram with method and integration | Hydrophobic impurities co-elute under generic gradients |
| Content | Water content + net peptide content | High-value material — content drives cost per mg |
| Batch linkage | Lot number on vial, COA and invoice | Prevents certificate reuse across lots |
| Consistency | Two or three consecutive lot COAs | Distinguishes a process from ad-hoc sourcing |
GLP-1 peptide sourcing checklist turns this into a working document.
Handling differences that matter
What changes with hydrophobicity
All three are lyophilized powders handled under the same general principles — cold, dry, dark, minimal freeze–thaw — but the hydrophobic modifications change the details:
- Dissolution: expect slower wetting; add solvent down the wall and allow time.
- Adsorption: at low concentrations, hydrophobic sequences adsorb more readily to plastic; use low-binding labware.
- Filtration: membrane choice affects recovery; pre-rinse and account for hold-up.
- Aggregation: hydrophobic segments increase the risk; avoid vortexing and high local concentrations.
GLP-1 peptide storage and handling covers the practical protocol.
What this comparison does not tell you
It does not tell you which compound is "better" — that is a research question, not a procurement question, and it is outside the scope of a supplier's competence. It also does not establish equivalence between salt forms, purity grades or suppliers. Those are separate verification problems, each with its own evidence requirements.
The Author's Take
Position. The GLP-1 category rewards buyers who slow down. The compounds are expensive, the analytical bar is high, and the market is full of material that looks right on a label. The winning behaviour is not finding the cheapest vial; it is refusing to buy without a batch-linked identity and purity package.
Reasoning. At this molecular weight and hydrophobicity, small analytical differences translate into large practical ones: a co-eluting impurity, a wrong salt form, or a 5% net-content gap changes what an experiment is actually testing. The cost of the vial is small compared with the cost of a wrong conclusion.
Disclosure. We supply all three compounds and benefit when buyers prefer documented material. We also decline orders where the buyer cannot describe a legitimate research use — a policy that costs us revenue and is, in our view, part of selling this category responsibly.
Frequently asked
Are semaglutide, tirzepatide and retatrutide interchangeable?
No. They differ in sequence, molecular weight, receptor profile and analytical behaviour. Each requires its own specification.
What molecular weight should the COA show?
The mass of the modified sequence for the salt form supplied. Reference values are listed in our sources; the batch COA is authoritative.
Do you provide a batch COA for each lot?
Yes. Every lot ships with a batch-specific COA, HPLC chromatogram and MS confirmation.
Are these products for human use?
No. All products are supplied for laboratory research only, not for human or veterinary use.
Sources & evidence
Molecular weights and receptor assignments below are cross-checked against public databases and regulatory assessments; the batch COA governs the material you receive.
- Semaglutide: PubChem CID 56843331; EMA product information — Ozempic EPAR.
- Tirzepatide: PubChem CID 166567236; EMA product information — Mounjaro EPAR.
- Retatrutide: not indexed in PubChem at the time of writing; reference mass taken from published clinical literature. Trial records: ClinicalTrials.gov search.
- Specification concepts: ICH Q6B — ICH quality guidelines.
Receptor assignments describe reported pharmacology of the research materials; they are not efficacy claims and not guidance for human use.
Products referenced in this guide
- Tirzepatide — 2–60 mg research formats
- Semaglutide — 2–50 mg research formats
- Retatrutide — 5–60 mg research formats
- Research peptide catalogue — full SKU list
- Wholesale & bulk supply — MOQ and documentation
- Testing methods — HPLC, MS, Karl Fischer
Cluster: the GLP-1 library
- Semaglutide vs tirzepatide vs retatrutide — the short comparison
- Semaglutide analytical profile — sequence and method notes
- Tirzepatide analytical profile — long-sequence analytics
- Retatrutide analytical profile — verification points
- GLP-1 sourcing checklist — what to verify
- GLP-1 storage and handling — practical protocol
- Peptide sequence notation — reading the sequence
- Identity by mass spectrometry — the verification method
- Lot-to-lot consistency — the trend view
- Net content and cost — the economics